UpcomingPDUFA target action date

Qtorin rapamycin 3.9% anhydrous gel

Palvella Therapeutics (PVLA)

Marketer take

The company calls it potentially the first FDA-approved therapy for this condition and is building commercial and medical affairs teams ahead of the date.

Sponsor company
Palvella Therapeutics (PVLA)
Indication
Microcystic lymphatic malformations
Therapeutic area
Dermatology, Rare disease
Event
PDUFA target action date
Date
Feb 28, 2027
Status
Upcoming
Source
company press release
Last verified
Nov 15, 2026

Dates and status come from the linked public source as of the last verified date. Spot an error or have an update?

Get alerts when FDA dates move